Kobayashi Satoshi

Inazaki Hiroshi, Kobayashi Satoshi, Anzai Yoko, Satoh Hisayoshi, Sato Shimpei, Inoue Maiko et al.

Ripasudil, added to maximum glaucoma therapy, significantly lowered intraocular pressure by 2.6 mmHg over one year. This offers a new option for patients with uncontrolled glaucoma.

Inazaki Hiroshi, Kobayashi Satoshi, Anzai Yoko, Satoh Hisayoshi, Sato Shimpei, Inoue Maiko et al.

Ripasudil, added to maximum glaucoma therapy, significantly lowered IOP by 2.8 mmHg in poorly controlled patients, achieving target pressure in nearly half and potentially delaying surgery.

Aihara Makoto, Ikeda Yoko, Mizoue Shiro, Arakaki Yoshikuni, Kita Naofumi, Kobayashi Satoshi

Switching glaucoma patients with chronic keratitis from BAK-latanoprost to SofZia-travoprost significantly improved corneal surface health without compromising IOP control, offering a better-tolerated treatment option.

Kobayashi Satoshi, Inoue Maiko, Yamane Shin, Sakamaki Kentaro, Arakawa Akira, Kadonosono Kazuaki

Preoperative bevacizumab before trabeculectomy for neovascular glaucoma showed good long-term (3+ years) intraocular pressure control, suggesting this approach effectively manages advanced cases.

Yamane Shin, Kadonosono Kazuaki, Inoue Maiko, Kobayashi Satoshi, Watanabe Yoichiro, Arakawa Akira

This study found that gas tamponade significantly accelerates sutureless vitrectomy wound closure compared to fluid, potentially reducing postoperative hypotony and complications.